References
- Kantarjian, O'Brien S, Smith T L, Cortes J, Giles F J, Beran M, et al. Results of Treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547–561
- Eric L, Sievers, Larson R A, Stadtmauer E A, Estey E, Lowenberg B, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244–3254
- Golay J, Di Gaetano N, Amico D, Cittera E, Barbui A M, Giavazzi R, et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br J Haematol 2005; 128: 310–317
- Cotter M, Rooney S, O'Marcaigh A, Smith O P. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 687–688
- Zwaan C M, Reinhardt D, Jurgens H, Huismans D R, Hahlen K, Smith O P, et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single-agent calicheamicin. Leukemia 2003; 17: 468–470
- Balduzzi A, Rossi V, Corral L, Bonanomi S, Longoni D, Rovelli A, et al. Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia 2003; 17: 2247–2248
- Carella A M, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, et al. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group. Leukemia 1993; 7: 196–199
- Philpott N, Mehta J, Treleaven J, Powles R, et al. Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia. Leuk Lymphoma 1994; 15: 127–130